There are scientific advancements that look promising for controlling and preventing the onset of Alzheimer's disease. Alzheimer's is such a complex disease that most experts anticipate that a drug that will control the disease will very likely contain a drug cocktail. The treatment that is only conjecture may include a regimen of drugs that is used to treat AIDS.
The progress in the search for a cure for Alzheimer's looks promising. Several Research scientists are being funded by The Alzheimer's Disease Association as well as additional resources from private and philanthropic organizations. Scientists are gaining insights how the disease progresses in the brain. Many Experts believe that a new generation of treatments will evolve that will prevent, slow or perhaps reverse the damaging effects of Alzheimer's disease.
The newest discovery in the alzheimer’s disease Market size research community is from the UK. A team of research scientist led by Dr. Emma Kidd at Cardiff University's Welsh School of Pharmacy recently completed a study showing that it is possible to decrease production of a small protein called amyloid (A*), This protein is believed to be the main cause of the disease. The research was funded by the Alzheimer's Society, the UK's leading care and research charity for Alzheimer's disease and other types of dementia.
Researchers at the University of California, Los Angeles have discovered a new brain imaging compound that shows promise by giving researchers a way to detect Alzheimer's disease earlier. This imaging molecule can detect and map the plaques and tangles in the brains of people with Alzheimer's disease.
This discovery could eventually lead to earlier diagnosis of the devastating disease. The compound is called FDDNP. FDDNP also holds promise as a research tool to evaluate new treatments for Alzheimer's. The study was funded in part by the National Institute on Aging (NIA), one of the National Institutes of Health (NIH).
Alzhemed is being developed by Neurochem Inc. This company is just months away from finding out if the drug developed by their Quebec-based company can actually slow the course of Alzheimer's disease. A clinical trial of the drug will wrap up in January, with results expected in the spring.
moiz heer